{"id":"fluvirin-tivf","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5–15","effect":"Myalgia (muscle pain)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluvirin contains inactivated (killed) influenza virus particles or viral antigens from three seasonal flu strains (hence TIVf for trivalent inactivated vaccine, formulated). When administered, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (primarily IgG) against the included influenza A and B strains. This allows the vaccinated individual to mount a rapid immune response upon exposure to circulating influenza viruses, reducing infection risk and disease severity.","oneSentence":"Fluvirin is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:50.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children ≥4 years of age"}]},"trialDetails":[{"nctId":"NCT02256488","phase":"PHASE3","title":"Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-09","conditions":"Prophylaxis: Influenza","enrollment":1561},{"nctId":"NCT01640327","phase":"PHASE3","title":"Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-07","conditions":"Human, Influenza","enrollment":126},{"nctId":"NCT01857206","phase":"PHASE3","title":"Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-05","conditions":"Influenza, Fever","enrollment":2055},{"nctId":"NCT01867021","phase":"PHASE4","title":"Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above","status":"COMPLETED","sponsor":"Novartis","startDate":"2013-05","conditions":"Influenza","enrollment":2902},{"nctId":"NCT01885117","phase":"PHASE3","title":"Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-08","conditions":"Human Influenza","enrollment":125},{"nctId":"NCT01209780","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":3116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)"],"phase":"marketed","status":"active","brandName":"Fluvirin(TIVf)","genericName":"Fluvirin(TIVf)","companyName":"Novartis","companyId":"novartis","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fluvirin (TIVf) is a vaccine used to prevent influenza in humans. It is a trivalent subunit inactivated vaccine that has been studied for its immunogenicity, safety, and tolerability in healthy subjects aged 50 years and above.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}